
BLFS
BioLife Solutions Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
24.610
Open
24.285
VWAP
24.35
Vol
15.62K
Mkt Cap
1.17B
Low
24.285
Amount
380.42K
EV/EBITDA(TTM)
256.04
Total Shares
46.07M
EV
1.09B
EV/OCF(TTM)
70.41
P/S(TTM)
12.22
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
25.69M
-15.96%
--
--
26.61M
+17.16%
--
--
27.03M
+12.91%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by 1.27% over the past three months. During the same period, the stock price has changed by 7.24%.
Revenue Estimates for FY2025
Revise Upward

+1.27%
In Past 3 Month
Stock Price
Go Up

+7.24%
In Past 3 Month
7 Analyst Rating

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 31.00 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy

Current: 24.600

Low
30.00
Averages
31.00
High
34.00

Current: 24.600

Low
30.00
Averages
31.00
High
34.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$30 -> $32
2025-08-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $32
2025-08-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.
Stephens
Stephens
Overweight
initiated
$30
2025-07-21
Reason
Stephens
Stephens
Price Target
$30
2025-07-21
initiated
Overweight
Reason
Stephens resumed coverage of BioLife Solutions with an Overweight rating and $30 price target and named the stock as the analyst's "Best Idea." BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment "represents a crown jewel asset" as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$27 → $30
2025-03-06
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$27 → $30
2025-03-06
Maintains
Strong Buy
Reason
Northland Capital Markets
Carl Byrnes
Buy
Maintains
$28 → $31
2025-01-08
Reason
Northland Capital Markets
Carl Byrnes
Price Target
$28 → $31
2025-01-08
Maintains
Buy
Reason
Benchmark
Robert Wasserman
Strong Buy
Reiterates
$30
2024-12-19
Reason
Benchmark
Robert Wasserman
Price Target
$30
2024-12-19
Reiterates
Strong Buy
Reason
Keybanc
Paul Knight
Buy
Maintains
$30 → $33
2024-12-13
Reason
Keybanc
Paul Knight
Price Target
$30 → $33
2024-12-13
Maintains
Buy
Reason
KeyBanc raised the firm's price target on BioLife Solutions to $33 from $30 and keeps an Overweight rating on the shares. BioLife, under its new CEO, has completed a quick succession of three asset sales, and the firm's proforma models show a high-growth and high-margin business with its dominance of freeze media for the cell, gene, and CAR-T markets, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for BioLife Solutions Inc (BLFS.O) is -3245.33, compared to its 5-year average forward P/E of -1566.32. For a more detailed relative valuation and DCF analysis to assess BioLife Solutions Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1566.32
Current PE
-3245.33
Overvalued PE
4237.46
Undervalued PE
-7370.10
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
91.77
Current EV/EBITDA
40.54
Overvalued EV/EBITDA
203.94
Undervalued EV/EBITDA
-20.41
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
8.88
Current PS
10.78
Overvalued PS
12.69
Undervalued PS
5.07
Financials
Annual
Quarterly
FY2025Q2
YoY :
+28.94%
25.42M
Total Revenue
FY2025Q2
YoY :
-14.09%
-1.12M
Operating Profit
FY2025Q2
YoY :
+184.86%
-15.84M
Net Income after Tax
FY2025Q2
YoY :
-26.67%
-0.33
EPS - Diluted
FY2025Q2
YoY :
-209.78%
-4.76M
Free Cash Flow
FY2025Q2
YoY :
-2.63%
61.86
Gross Profit Margin - %
FY2025Q2
YoY :
-102.56%
0.36
FCF Margin - %
FY2025Q2
YoY :
+120.92%
-62.30
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 14923.6% over the last month.
Sold
0-3
Months
35.3M
USD
15
3-6
Months
2.3M
USD
32
6-9
Months
641.3K
USD
12
0-12
Months
3.2M
USD
27
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
770.0
Volume
1
6-9
Months
7.5K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
28.0K
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 14923.6% over the last month.
Sold
0-3
Months
35.3M
USD
15
3-6
Months
2.3M
USD
32
6-9
Months
641.3K
USD
12
0-12
Months
3.2M
USD
27
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BLFS News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
16:15:05
BioLife Solutions raises 2025 revenue vew to $100M-$103M from $95.5M-$99.0M

2025-08-07
16:14:10
BioLife Solutions reports Q2 EPS (33c), consensus (1c)

2025-07-28 (ET)
2025-07-28
08:07:03
BioLife Solutions purchases $2M of convertible notes in Pluristyx

Sign Up For More Events
Sign Up For More Events
News
4.0
08-12NASDAQ.COMBioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
9.5
08-07NASDAQ.COMMariMed Inc. (MRMD) Reports Break-Even Earnings for Q2
4.0
07-25NASDAQ.COMPeek Under The Hood: SPSM Has 16% Upside
Sign Up For More News
People Also Watch

HROW
Harrow Inc
39.640
USD
+2.11%

NVEE
NV5 Global Inc
22.140
USD
+0.49%

FVRR
Fiverr International Ltd
22.630
USD
+1.16%

MRVI
Maravai LifeSciences Holdings Inc
2.630
USD
+0.77%

TBLA
Taboola.com Ltd
3.281
USD
-1.17%

SCSC
Scansource Inc
43.350
USD
+1.76%

CNNE
Cannae Holdings Inc
17.880
USD
+0.39%

DSP
Viant Technology Inc
9.470
USD
-0.32%

IMKTA
Ingles Markets Inc
64.290
USD
+0.19%

FOXF
Fox Factory Holding Corp
29.600
USD
-0.03%
FAQ

What is BioLife Solutions Inc (BLFS) stock price today?
The current price of BLFS is 24.6 USD — it has increased 1.07 % in the last trading day.

What is BioLife Solutions Inc (BLFS)'s business?

What is the price predicton of BLFS Stock?

What is BioLife Solutions Inc (BLFS)'s revenue for the last quarter?

What is BioLife Solutions Inc (BLFS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for BioLife Solutions Inc (BLFS)'s fundamentals?

How many employees does BioLife Solutions Inc (BLFS). have?
